Janssen-Cilag International NV
janssen.comTotal trials
67
Active
1
Phase 3
24
Total enrollment
26,232
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ustekinumab | — | — | — | — | 2 |
Next readouts
- 2032-08-31
Top conditions
- Healthy19
- Schizophrenia11
- Multiple Myeloma6
- Hepatitis C, Chronic3
- Psoriasis3
- Pain2
- Hepatitis C2
- Chronic Hepatitis C1
Frequently asked questions about Janssen-Cilag International NV
- How many clinical trials does Janssen-Cilag International NV have on ClinicalTrials.gov?
- Janssen-Cilag International NV is listed as the lead sponsor on 67 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Janssen-Cilag International NV's trials are in Phase 3?
- 24 of Janssen-Cilag International NV's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Janssen-Cilag International NV focus on?
- Janssen-Cilag International NV's most-studied conditions on ClinicalTrials.gov are Healthy, Schizophrenia, Multiple Myeloma, Hepatitis C, Chronic, Psoriasis.
- When are Janssen-Cilag International NV's next clinical trial readouts?
- Janssen-Cilag International NV has 1 upcoming primary-completion readout tracked here; the soonest is “A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis”, expected around 2032-08-31.